Insmed, Inc.
INSM
$143.83
-0.45%
Insmed, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, operating primarily within the biotechnology sector. The company has established a distinct competitive identity as a commercial-stage player with a specialized portfolio in respiratory diseases, anchored by its two marketed products, Arikayce and Brinsupri, while advancing a pipeline across immunology, inflammation, and neuro-rare diseases. The current investor narrative is heavily centered on the company's growth trajectory from its commercial products and the progress of its clinical-stage pipeline, with recent attention likely driven by quarterly financial results and clinical updates that shape the debate around its path to profitability and long-term valuation.…
INSM
Insmed, Inc.
$143.83
Related headlines
Investment Opinion: Should I buy INSM Today?
Rating: Hold. The core thesis is that while Insmed's commercial growth is impressive, the extreme valuation and unsustainable cash burn create an asymmetric risk/reward profile that favors waiting for a better entry point or clearer path to profitability.
Supporting this view, the stock trades at a stratospheric 61.3x sales, a 192.9x forward PE (though not meaningful due to losses), and an EV/Sales of 49.6x, all indicating a massive growth premium. While Q4 revenue growth of 152.6% is exceptional, it must be sustained to justify these multiples. The improving gross margin (82.5% in Q4) is a positive, but it is overwhelmed by net and operating margins deeply in negative territory (-124.5% and -94.6%, respectively). Analyst unanimity is a bullish signal, but without specific target prices, the implied upside is unclear.
The thesis would upgrade to Buy if the PS ratio compressed meaningfully (e.g., toward 30x) on sustained high growth, or if the company announced a credible path to positive cash flow. It would downgrade to Sell if quarterly revenue growth decelerated below 50%, cash burn accelerated, or a key pipeline candidate failed. Relative to its history and biotech peers, Insmed is unequivocally overvalued, trading on hope and momentum rather than current fundamentals.
Sign up to view all
INSM 12-Month Price Forecast
Insmed is a binary story where spectacular growth is counterbalanced by perilous valuation and financing risks. The neutral stance reflects the high probability of the base case—volatile, range-bound trading—as the market digests whether growth can outrun burn. The unanimous analyst bullishness following the pullback is notable but may be early. The stance would upgrade to bullish on evidence of sustained >100% growth coupled with a decelerating cash burn rate. It would turn bearish on any meaningful growth deceleration or a dilutive capital raise, either of which could trigger the valuation air pocket.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $186.98 and implied upside of +30.0% versus the current price.
Average Target
$186.98
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$115 - $187
Analyst target range
The stock is covered by 8 analysts, and recent institutional ratings from firms like Morgan Stanley, Mizuho, and Wells Fargo show a unanimously bullish stance, with actions including upgrades to 'Overweight' and reiterated 'Buy' or 'Outperform' ratings. The consensus sentiment is strongly positive, though a specific average target price and implied upside are not provided in the dataset; the presence of multiple recent reaffirmations and an upgrade suggests analysts see value at current levels following the price pullback. The target price range is also not specified in the data, but the high degree of bullish consensus from major firms implies the low end of any range would factor in commercial execution risks or pipeline setbacks, while the high end would assume successful clinical readouts, market expansion, and a path to profitability. The pattern of recent ratings in March 2026, including an upgrade from Morgan Stanley, indicates analysts are interpreting recent developments or the price decline as a buying opportunity, reinforcing a constructive outlook despite the stock's weak technical performance and challenging fundamentals.
Bulls vs Bears: INSM Investment Factors
The investment debate for Insmed is a classic high-growth biotech tension between explosive commercial traction and an unsustainable valuation that demands flawless future execution. The bull case, supported by 152.6% revenue growth and unanimous analyst bullishness, is currently stronger on fundamental momentum, but it rests on a precarious foundation. The single most important tension is whether the company's blistering revenue growth can accelerate fast enough to justify its extreme 61.3x PS multiple before cash burn forces dilutive financing or investor patience wears thin. The bear case, anchored by massive losses and an extreme valuation premium, presents a formidable risk of significant downside if growth decelerates even slightly.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $263.8 million grew 152.6% year-over-year, demonstrating powerful commercial traction for Arikayce and Brinsupri. This acceleration from prior quarters suggests the company is successfully scaling its marketed products.
- Unanimous Analyst Bullishness: All 8 covering analysts hold a Buy or equivalent rating, with recent upgrades from major firms like Morgan Stanley in March 2026. This strong consensus indicates institutional confidence in the company's strategy and valuation following the stock's pullback.
- Improving Gross Margin Profile: Gross margin expanded to 82.5% in Q4 2025, up from 79.4% in Q3, indicating operating leverage on significantly higher revenue. This trend is critical for the long-term path to profitability.
- Strong Short-Term Liquidity: A current ratio of 3.83 provides ample liquidity to fund near-term operations despite heavy cash burn. This financial cushion reduces immediate solvency risk as the company invests in growth.
Bearish
- Extreme Valuation Premium: A trailing Price-to-Sales ratio of 61.3x is massively above the typical biotech range of 5x-15x, pricing in near-perfect execution. This leaves the stock vulnerable to severe multiple compression if growth falters or clinical results disappoint.
- Massive and Worsening Losses: Q4 2025 net income was -$328.5 million with an EPS of -$1.54, and losses have widened sequentially from Q3. The company is far from profitability, with a negative ROE of -172.8%.
- Unsustainable Cash Burn: Trailing twelve-month free cash flow is -$997.6 million, and Q4 operating cash flow was -$247.6 million. This burn rate necessitates future capital raises, which could be dilutive to shareholders given the high valuation.
- Technical Downtrend and Weak Momentum: The stock is down -12.84% over 6 months and -18.43% YTD, trading near the middle of its 52-week range. Weak 3-month momentum (-10.49%) and negative relative strength across all periods signal a loss of investor enthusiasm.
INSM Technical Analysis
The stock is in a pronounced downtrend from its recent highs, evidenced by a 1-year price change of +98.87% but a 6-month decline of -12.84% and a year-to-date drop of -18.43%. Currently trading at $144.48, the price sits approximately 67.8% of its 52-week range ($63.81 to $212.75), indicating a retreat from highs and positioning the stock in a middle-ground area that reflects a loss of momentum after a strong prior-year rally. Recent momentum has been weak, with the stock down -10.49% over the past three months and up a modest 1.25% over the past month, suggesting a potential stabilization or minor bounce within the context of a broader corrective phase; this short-term stabilization diverges from the negative intermediate-term trend and may signal a consolidation before the next directional move. Key technical levels are clearly defined by the 52-week high of $212.75 as major resistance and the 52-week low of $63.81 as critical support; a sustained break above the recent downtrend resistance near $165-170 would be needed to signal a reversal, while a breakdown below the $140 level could target lower support. With a beta of 1.101, the stock exhibits slightly higher volatility than the broader market, which is typical for a biotech name and necessitates careful risk management given the current technical weakness.
Beta
1.10
1.10x market volatility
Max Drawdown
-35.7%
Largest decline past year
52-Week Range
$64-$213
Price range past year
Annual Return
+103.1%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | +3.4% | +8.5% |
| 3m | -7.9% | +2.8% |
| 6m | -9.9% | +4.6% |
| 1y | +103.1% | +32.3% |
| ytd | -18.8% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Revenue growth is accelerating significantly, with Q4 2025 revenue reaching $263.8 million, representing a robust year-over-year growth rate of 152.6%. This growth is a substantial improvement over prior quarters, indicating strong commercial execution for its products, Arikayce and Brinsupri, which are driving the top-line expansion. The company remains deeply unprofitable, reporting a net income of -$328.5 million and an EPS of -$1.54 for Q4 2025, despite a healthy gross margin of 82.5%. Losses have widened sequentially from Q3's net income of -$370.0 million, but the gross margin improved from 79.4%, suggesting some operating leverage on significantly higher revenue, though high R&D and SG&A expenses continue to pressure the bottom line. The balance sheet shows a debt-to-equity ratio of 1.04, indicating a leveraged capital structure, while the current ratio of 3.83 suggests strong short-term liquidity. However, cash flow remains a critical concern, with trailing twelve-month free cash flow deeply negative at -$997.6 million and operating cash flow for Q4 alone at -$247.6 million, highlighting the company's heavy cash burn as it funds commercial growth and clinical development, necessitating ongoing access to capital markets.
Quarterly Revenue
$263843000.0B
2025-12
Revenue YoY Growth
+1.52%
YoY Comparison
Gross Margin
+0.82%
Latest Quarter
Free Cash Flow
$-997575000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is an exceptionally high 61.3x, while the forward-looking metric is not explicitly provided but can be inferred from the market cap and analyst revenue estimates, suggesting the market is pricing in tremendous future growth. The forward-looking expectation is embedded in a forward PE of 192.9, which, while not applicable due to losses, underscores the market's long-dated profit expectations. Insmed trades at a significant premium to typical biotechnology industry averages, where PS ratios often range from 5x to 15x for commercial-stage companies; its 61x sales multiple implies investors are assigning value almost entirely to future pipeline success and rapid revenue scaling, not current fundamentals. Historically, the stock's own PS ratio has been volatile but consistently elevated, with a reading of 140.9x as of Q4 2025 per historical data; the current 61.3x represents a contraction from that peak but remains extremely high by any standard, indicating that while the valuation has cooled from prior extremes, the stock still prices in near-perfect execution and clinical success, leaving little room for disappointment.
PE
-29.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's profound lack of profitability and unsustainable cash consumption. With a Q4 2025 net loss of -$328.5 million and TTM free cash flow of -$997.6 million, Insmed is burning cash at an alarming rate to fund commercial growth and R&D. A debt-to-equity ratio of 1.04 adds financial leverage to this operational risk, increasing the cost and urgency of future capital raises. The path to profitability remains distant, making the company entirely dependent on external financing and flawless commercial execution to avoid a liquidity crisis.
Market & Competitive Risks are dominated by extreme valuation compression risk. Trading at a PS ratio of 61.3x—roughly 4-12x the industry norm—the stock is priced for perfection. Any disappointment in revenue growth, pipeline progress, or a shift in market sentiment away from high-multiple, loss-making biotechs could trigger a severe derating. The stock's beta of 1.101 indicates slightly higher volatility than the market, amplifying downside moves during sector-wide selloffs. Competitive threats to its respiratory franchise or clinical setbacks for pipeline candidates like brensocatib are not priced in, given the current premium.
Worst-Case Scenario involves a combination of slowing revenue growth, a failed clinical trial, and a tightening capital market. This could lead to a vicious cycle: missed forecasts trigger multiple compression, the high cash burn necessitates a dilutive equity offering at a depressed price, and loss of investor confidence accelerates the decline. In this adverse scenario, the stock could realistically revisit its 52-week low of $63.81, representing a downside of approximately -56% from the current price of $144.48. The historical max drawdown of -35.67% suggests the stock is capable of severe corrections when sentiment sours.
FAQ
The key risks are, in order of severity: 1) Valuation & Financing Risk: The extreme PS multiple of 61.3x could collapse if growth slows, and the -$997.6M TTM cash burn may force a dilutive equity offering. 2) Profitability Risk: Deepening net losses (-$328.5M in Q4) and a negative ROE of -172.8% show no near-term path to profits. 3) Operational Risk: Revenue is concentrated in two products (Arikayce, Brinsupri); any commercial setback would severely impact growth. 4) Market Risk: With a beta of 1.1, the stock is volatile and could fall sharply in a biotech sector downturn.
The 12-month outlook presents three scenarios. The Base Case (50% probability) sees range-bound trading between $130-$165 as strong growth moderates and high valuation persists. The Bull Case (25% probability), driven by sustained >100% growth and positive pipeline news, targets a return to the $190-$212 range near prior highs. The Bear Case (25% probability), triggered by growth disappointment or a dilutive financing, could see the stock fall to $64-$100, revisiting its 52-week low. The Base Case is most likely, implying limited near-term upside from the current $144.48 price without a fundamental improvement in profitability.
INSM is dramatically overvalued by traditional metrics. Its Price-to-Sales ratio of 61.3x is 4-12 times higher than the typical range for commercial-stage biotech peers. A forward PE of 192.9x (though not meaningful due to losses) and an EV/Sales of 49.6x further confirm the extreme premium. The valuation is not based on current fundamentals but on expectations of continued hyper-growth and future pipeline success. This implies the market is pricing in flawless execution and leaves no room for error, creating significant downside risk if growth slows.
INSM is a speculative buy only for investors with a very high risk tolerance and a long-term horizon. The 152.6% revenue growth is compelling, but it is counterbalanced by a massive 61.3x sales valuation and unsustainable cash burn (-$997.6M TTM). With all 8 analysts bullish, there is institutional confidence, but the stock requires near-perfect execution. For most investors, it is not a good buy at current levels; waiting for a lower entry price after a potential valuation reset or for evidence of decelerating cash burn would improve the risk/reward profile significantly.
INSM is strictly a long-term investment for those betting on pipeline maturation and a path to profitability. It pays no dividend and is in a capital-intensive growth phase with high volatility (beta 1.101), making it unsuitable for short-term trading or income portfolios. The investment thesis hinges on clinical and commercial developments that will unfold over years, not quarters. Given the cash burn and need for future catalysts, a minimum holding period of 3-5 years is suggested to weather volatility and allow the story to develop. Short-term traders face significant risk from earnings volatility and sentiment shifts.
